316 related articles for article (PubMed ID: 28219368)
21. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
22. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.
Kidera Y; Kawakami H; Sakiyama T; Okamoto K; Tanaka K; Takeda M; Kaneda H; Nishina S; Tsurutani J; Fujiwara K; Nomura M; Yamazoe Y; Chiba Y; Nishida S; Tamura T; Nakagawa K
PLoS One; 2014; 9(7):e101902. PubMed ID: 25020203
[TBL] [Abstract][Full Text] [Related]
24. Effect of Honey and Royal Jelly against Cisplatin-Induced Nephrotoxicity in Patients with Cancer.
Osama H; Abdullah A; Gamal B; Emad D; Sayed D; Hussein E; Mahfouz E; Tharwat J; Sayed S; Medhat S; Bahaa T; Abdelrahim MEA
J Am Coll Nutr; 2017 Jul; 36(5):342-346. PubMed ID: 28548561
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
26. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
[TBL] [Abstract][Full Text] [Related]
27. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity.
Sendur MA; Aksoy S; Yaman S; Arik Z; Tugba Kos F; Akinci MB; Civelek B; Yildirim Ozdemir N; Uncu D; Zengin N
J BUON; 2013; 18(1):274-80. PubMed ID: 23613416
[TBL] [Abstract][Full Text] [Related]
28. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
[TBL] [Abstract][Full Text] [Related]
29. Nordihydroguaiaretic acid ameliorates cisplatin induced nephrotoxicity and potentiates its anti-tumor activity in DMBA induced breast cancer in female Sprague-Dawley rats.
Mundhe NA; Kumar P; Ahmed S; Jamdade V; Mundhe S; Lahkar M
Int Immunopharmacol; 2015 Sep; 28(1):634-42. PubMed ID: 26247680
[TBL] [Abstract][Full Text] [Related]
30. [A clinical phase II trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
Nishikawa H; Ogura T; Tsubura E
Gan To Kagaku Ryoho; 1998 Jan; 25(1):89-96. PubMed ID: 9464334
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway.
Wainford RD; Weaver RJ; Stewart KN; Brown P; Hawksworth GM
Toxicology; 2008 Jul; 249(2-3):184-93. PubMed ID: 18583013
[TBL] [Abstract][Full Text] [Related]
32. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
[TBL] [Abstract][Full Text] [Related]
33. Multiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patients.
Liu HE; Bai KJ; Hsieh YC; Yu MC; Lee CN; Chang JH; Hsu HL; Lu PC; Chen HY
Biomed Res Int; 2014; 2014():937429. PubMed ID: 25250341
[TBL] [Abstract][Full Text] [Related]
34. [Magnesium premedication prevents Cisplatin-induced nephrotoxicity in patients with esophageal and hypopharyngeal cancer].
Hirai S; Kaida S; Ito T; Hasebe S; Ueno M; Udagawa H; Hayashi M
Gan To Kagaku Ryoho; 2013 Jun; 40(6):743-7. PubMed ID: 23863650
[TBL] [Abstract][Full Text] [Related]
35. [A clinical phase III trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
Nishikawa H; Nakabayashi T; Nakai Y; Kurita Y; Fukuoka M; Onoshi T; Ogura T; Sakuma A; Niitani H; Tsubura E
Gan To Kagaku Ryoho; 1998 Jan; 25(1):97-109. PubMed ID: 9464335
[TBL] [Abstract][Full Text] [Related]
36. Urine ratio of neutrophil gelatinase-associated lipocalin to creatinine as a marker for early detection of cisplatin-associated nephrotoxicity.
Shahbazi F; Sadighi S; Dashti-Khavidaki S; Shahi F; Mirzania M
Iran J Kidney Dis; 2015 Jul; 9(4):306-10. PubMed ID: 26174458
[TBL] [Abstract][Full Text] [Related]
37. Magnesium depletion enhances cisplatin-induced nephrotoxicity.
Lajer H; Kristensen M; Hansen HH; Nielsen S; Frøkiaer J; Ostergaard LF; Christensen S; Daugaard G; Jonassen TE
Cancer Chemother Pharmacol; 2005 Nov; 56(5):535-42. PubMed ID: 15947931
[TBL] [Abstract][Full Text] [Related]
38. Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide.
Saleh S; El-Demerdash E
Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):91-7. PubMed ID: 15998355
[TBL] [Abstract][Full Text] [Related]
39. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
40. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
